482 assets in Prostate Cancer

Therapeutic assets addressing Prostate Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Prostate Cancer	Australian and New Zealand Urogenital and Prostate Cancer Trials Group	P3	B (61)
ly01005 Prostate Cancer	The First Affiliated Hospital of Xiamen University	P3	B (61)
Metformin Prostate Cancer	University of Arkansas	P4	B (61)
Oxaliplatin Prostate Cancer	Parabilis Medicines, Inc.	P2	B (61)
Testosterone Cipionate Prostate Cancer	University of Miami	P4	B (61)
Testosterone Undecylate Prostate Cancer	Roswell Park Cancer Institute	P4	B (61)
Bet Bromodomain Inhibitor Zen-3694 Prostate Cancer	Rahul Aggarwal	P2	B (60)
Buserelin Prostate Cancer	NRG Oncology	P3	B (60)
Cetrelimab Prostate Cancer	Janssen Research & Development, LLC	P2	B (60)
Cis-Diamminedichloroplatinum Ii Prostate Cancer	The First Affiliated Hospital of Xiamen University	P3	B (60)
Decapeptyl Prostate Cancer	Cancer Research Antwerp	P4	B (60)
Gm-Csf Prostate Cancer	University of Wisconsin, Madison	P2	B (60)
HC-1119 Prostate Cancer	Hinova Pharmaceuticals Inc.	P3	B (60)
Hydrocortisone Prostate Cancer	National Cancer Institute (NCI)	P3	B (60)
Letrozole Prostate Cancer	Case Comprehensive Cancer Center	P4	B (60)
Mevrometostat Prostate Cancer	Pfizer	P3	B (60)
Midazolam Prostate Cancer	The Netherlands Cancer Institute	P4	B (60)
Niclosamide Prostate Cancer	University of California, Davis	P2	B (60)
Omeprazole Prostate Cancer	Wake Forest University Health Sciences	P2	B (60)
Padeliporfin Prostate Cancer	Steba Biotech S.A.	P3	B (60)
Radium Ra-223 Prostate Cancer	University of California, San Francisco	P3	B (60)
Ropivacaine Prostate Cancer	Memorial Sloan Kettering Cancer Center	P4	B (60)
Tislelizumab Prostate Cancer	Shanghai Changzheng Hospital	P2	B (60)
Trimethoprim Prostate Cancer	University of California, San Diego	P4	B (60)
68ga-psma Prostate Cancer	The First Affiliated Hospital of Anhui Medical University	P2	B (59)
Hydroxychloroquine Prostate Cancer	Lionel.D.Lewis, MD	P2	B (59)
Nivolumab Prostate Cancer	Exelixis	P3	B (59)
Regramostim Prostate Cancer	University of Wisconsin, Madison	P2	B (59)
Tranexamic Acid Prostate Cancer	Konkuk University Medical Center	P4	B (59)
Abemaciclib Prostate Cancer	OHSU Knight Cancer Institute	P3	B (58)
Cabozantinib Prostate Cancer	Exelixis	P3	B (58)
Carboplatin Prostate Cancer	Alliance for Clinical Trials in Oncology	P3	B (58)
Celecoxib Prostate Cancer	OHSU Knight Cancer Institute	P2/3	B (58)
Fulvestrant Prostate Cancer	TYK Medicines, Inc	P2	B (58)
hs-20093 Prostate Cancer	Jiangsu HengRui Medicine Co., Ltd.	P2	B (58)
Ibuprofen Prostate Cancer	Albany Medical College	P4	B (58)
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer Prostate Cancer	Canadian Cancer Trials Group	P2	B (58)
Olaparib Prostate Cancer	MOMA Therapeutics	P2	B (58)
Pioglitazone Prostate Cancer	St. Louis University	P3	B (58)
Sar-Bispsma, Cu-64 Prostate Cancer	Clarity Pharmaceuticals Ltd	P3	B (58)
Saruparib Prostate Cancer	AstraZeneca	P3	B (58)
177lu-psma Prostate Cancer	Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS	P2	B (57)
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone Prostate Cancer	Wake Forest University Health Sciences	P4	B (57)
Atorvastatin Prostate Cancer	Tampere University Hospital	P3	B (57)
Dkf-Ma102 Prostate Cancer	Dongkook Pharmaceutical Co., Ltd.	P3	B (57)
Hyaluronidase Zzxf Prostate Cancer	Mayo Clinic	P2	B (57)
Indocyanine Green Prostate Cancer	Kaiser Permanente	P4	B (57)
Itraconazole Prostate Cancer	University of Chicago	P2	B (57)
Ketoconazole Prostate Cancer	The University of Texas Health Science Center, Houston	P3	B (57)
Lorigerlimab Prostate Cancer	MacroGenics	P2	B (57)

Showing 51 to 100 of 482 assets

PreviousPage 2 of 10Next